Monte Rosa Therapeutics, Inc. (GLUE) Net income 2021–2026
Monte Rosa Therapeutics, Inc. (GLUE) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$38.6MFY2026 · since FY2021: -$35.9M → -$38.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$38.6M | +46.9% |
| FY2025 | -$72.7M | +46.3% |
| FY2024 | -$135.4M | -24.7% |
| FY2023 | -$108.5M | -46.7% |
| FY2022 | -$74.0M | -106.1% |
| FY2021 | -$35.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GLUE financial trends
GLUE RevenueGLUE Net marginGLUE Gross profitGLUE Gross marginGLUE Operating incomeGLUE Operating marginGLUE Operating cash flowGLUE Free cash flowGLUE Capital expendituresGLUE Return on equityGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Total liabilitiesGLUE Shareholders’ equityGLUE overview →